Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Consumer Health Products Senior Editor
Washington DC, USA
17+ years of experience
HBW Insight
By Malcolm Spicer 31 Oct 2021
While working to improve the quality of VMS products available in the US and to provide information on the products to consumers, the ODS doesn’t have authority to impose change on the industry or in the marketplace.
HBW Insight
By Malcolm Spicer 13 Aug 2021
Rejection of two firms’ proposals for using hemp-derived CBD in supplement isn’t stirring US businesses selling CBD supplements to pull products from market. For one firm that filed an unsuccessful NDI notification for full-spectrum hemp extract CBD, FDA rejection was agenda item with numerous other business, regulatory and legislative developments in its latest quarter.
HBW Insight
By Malcolm Spicer 22 Jun 2020
FDA and FTC continue adding to total each has made during novel coronavirus pandemic. FTC's latest include peroxide gel and licorice as treatments; FDA’s emphasizes in warnings that three businesses' tests were not approved for OTC sales or for home use.
HBW Insight
By Malcolm Spicer 11 Dec 2019
Senate's Over-the-Counter Monograph Safety, Innovation, and Reform Act goes next for consideration by House, which has had a bill by the same title on its floor for a vote since it was passed by Energy and Commerce Committee in late June.
Topic FDA Legislation OTC Drugs
HBW Insight
By Malcolm Spicer 05 Jul 2019
"We seem to be headed toward a confusing, uneven, and potentially risky market in CBD products. This situation creates an opportunity for Congress to take action," say Joshua Sharfstein and Pieter Cohen in NEJM. Additionally, GW Pharma exec says FDA should reign in the "unfettered" production and sales of food and supplements containing CBD , hemp or other cannabis-based ingredients to prevent potential harm to consumers.
Topic FDA Policy & Regulation
HBW Insight
By Malcolm Spicer 03 Jul 2019
Scott Gottlieb claimed higher profile than most previous FDA commissioners with frequent Twitter posts and by including his remarks in many agency communications to industries and consumers. In his nearly two years in post, he also had more central role in FDA initiatives in areas such as keeping unsafe products labeled as supplements off the market and explaining why hemp and CBD are available and supplements even though FDA considers the products noncompliant as dietary ingredients.
Topic FDA
HBW Insight
25 Jul 2022
HBW Insight
22 Jul 2022
HBW Insight
22 Jul 2022
HBW Insight
20 Jul 2022
HBW Insight
19 Jul 2022
HBW Insight
19 Jul 2022
HBW Insight
13 Jul 2022
HBW Insight
12 Jul 2022
HBW Insight
06 Jul 2022
HBW Insight
05 Jul 2022
HBW Insight
24 Jun 2022
HBW Insight
23 Jun 2022
HBW Insight
22 Jun 2022
HBW Insight
21 Jun 2022
HBW Insight
20 Jun 2022
